PO.TB02.02 · 肿瘤生物学

定量三维组织学:在完整FFPE标本中开展百万细胞尺度的空间多组学

Quantitative 3D histology: Million-cell-scale spatial multi-omics in intact FFPE specimens

海报缩略图:定量三维组织学:在完整FFPE标本中开展百万细胞尺度的空间多组学
编号 713 展板 3 时间 4/19 02:00–05:00 区域 Section 29 主讲 Hei Ming Lai
分会场 Molecular Pathology
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Lichun Zhang1, William C. S. Cho2, Li Joshua3, Molly Li4, Tony S. Mok4, Hei Ming Lai1

1Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong,2Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong,3Pathology, University of Hong Kong, Hong Kong, Hong Kong,4Chinese University of Hong Kong, Hong Kong, Hong Kong

摘要 Abstract

中文摘要
癌症在患者内部和患者之间均表现出深刻的异质性,涵盖从单个细胞表型到复杂微环境生态位的范围。现有技术无法在整体保留天然组织结构的同时捕捉这种多尺度复杂性。在此,我们提出一个定量三维组织学平台,能够在完整的福尔马林固定石蜡包埋(FFPE)标本中实现空间分辨、百万细胞尺度的多组学分析。它消除了组织病理学中的抽样误差和主观性,并促进定量表型分析以指导治疗中的患者选择。 我们应用该平台对多种癌症标本进行分析,揭示了癌-神经相互作用、癌-免疫细胞相互作用,并通过每个样本>50万个细胞中的归一化膜比值(NMR),为可干预靶点(包括TROP2和HER2)生成定量的连续评分。我们还在被认定为正常组织的组织块中识别出漏诊的癌症、癌前病变和淋巴血管侵犯,以及由于随机标本切取这一根本局限而在二维定量数字病理工作中出现的决策困境和错误。 在开发该平台过程中,我们设计了用于低温FFPE抗原修复的新颖化学方法,以防止生物分子损伤,随后采用定制的超分子反应系统,使抗体能够深度渗透,从而在>1,000 μm厚的标本中实现高达28重的多重免疫染色。非破坏性组织透明化结合光片显微镜,随后以光学切片方式在三维中捕获整个标本。然后我们训练了一系列神经网络,以在细胞的天然三维位置中以精确的细胞几何形态分割单个细胞,从而能够计算到组织边界和结构(血管、神经)的距离,以及细胞类型之间的空间关系。这些三维掩膜量化了主要亚细胞区室中的标志物表达,为每个细胞生成连续的分子评分。 关键在于,组织在整个处理过程中保持结构和分子上的完整。三维分析前后的比较分析显示,H&E、免疫组化、全基因组测序、bulk RNA-seq、激光捕获质谱蛋白质组学和二维空间转录组学的结果无法区分。我们展示了将二维空间转录组学数据整合到三维体积中以进行全面单细胞分子分析的可行性。此外,三维组织学流程无需专门设备,可完全自动化,并可推广至各种组织类型,从而在空间背景驱动治疗决策的精准肿瘤学应用中实现快速的临床部署。 我们的技术解决了当前二维病理学方法的根本局限,在多种癌症中具有广泛的适用性。
查看英文原文 English abstract
Cancer exhibits profound heterogeneity both within and between patients, spanning from individual cell phenotypes to complex microenvironmental niches. Current technologies fail to capture this multiscale complexity while preserving native tissue architecture holistically. Here we present a quantitative 3D histology platform that enables spatially resolved, million-cell-scale multi-omic profiling of intact formalin-fixed paraffin-embedded (FFPE) specimens. It eliminates sampling error and subjectivity in histopathology, and facilitates quantitative phenotyping to guide patient selection in treatments. We applied this platform to profile diverse cancer specimens, uncovering cancer-nerve interactions, cancer-immune cell interactions, and generating quantitative continuous scores for actionable targets, including TROP2 and HER2, through normalised membrane ratios (NMRs) in >0.5 million cells per sample. We also identified missed cancers, pre-cancerous lesions, and lymphovascular invasion in designated normal tissue blocks, as well as decision dilemmas and errors in 2D quantitative digital pathology efforts, due to the fundamental limitations offered by a random specimen cut. In developing this platform, we devised novel chemistry for low-temperature FFPE retrieval to prevent biomolecular damage, followed by custom supramolecular reaction systems that enable deep antibody penetration for up to 28-plex multiplexed immunostaining in > 1,000 μm-thick specimens. Non-destructive tissue clearing, coupled with light-sheet microscopy, then captures the entire specimen in 3D with optical sectioning. We then trained a family of neural networks to segment individual cells in their native 3D positions with precise cellular geometry, allowing computation of distances to tissue boundaries and features (vessels, nerves), as well as spatial relationships between cell types. These 3D masks quantify marker expression across major subcellular compartments, generating continuous molecular scores for each cell. Crucially, tissues remain structurally and molecularly intact throughout processing. Comparative analyses pre- and post-3D profiling show indistinguishable results for H&E, immunohistochemistry, whole-genome sequencing, bulk RNA-seq, laser-capture mass spectrometry proteomics, and 2D spatial transcriptomics. We demonstrate the feasibility of integrating 2D spatial transcriptomic data into the 3D volume for comprehensive single-cell molecular profiling. Moreover, the 3D histology pipeline requires no specialized equipment, is fully automatable, and generalizes across tissue types, enabling rapid clinical deployment for precision oncology applications where spatial context drives therapeutic decisions. Our technology addresses the fundamental limitations of current 2D pathology methods, with broad applicability across multiple cancers.
利益披露 Disclosure
L. Zhang, None.. W. Cho, None.. L. Joshua, None.. M. Li, None. T. S. Mok, Illumos Limited Stock, Stock Option. H. Lai, Illumos Limited Stock.

← 返回 AACR 2026 检索